Phathom Pharmaceuticals Stock Discussion

$Phathom Pharmaceuticals (PHAT.US)$ Earnings announced for November 7 and an immediate effect on the price.

$Phathom Pharmaceuticals (PHAT.US)$ november 11 earnings date will deliver a knock out blow

$Phathom Pharmaceuticals (PHAT.US)$ looking PHAT!! 👌  watching for increased vol. here.

$Phathom Pharmaceuticals (PHAT.US)$ breaking free of the shackles..! up she goes

$Phathom Pharmaceuticals (PHAT.US)$ would be nice if the shorts would just give it up already. oh well, longer time to build a bag.

$Phathom Pharmaceuticals (PHAT.US)$ Lots of nervous trading going on. Once the shake out of shorters has been completed in a few weeks time and with the earnings on 8/8 this baby will go north

$Phathom Pharmaceuticals (PHAT.US)$ In a report released today,  from Needham maintained a Buy rating on Phathom Pharmaceuticals ( – ), with a price target of $26.00.
Joseph Stringer has given his Buy rating due to a combination of factors surrounding the recent developments at Phathom Pharmaceuticals. Stringer’s optimism is anchored in the approval of Voquezna for Non-Erosive GERD (NERD), a market considerably larger than the drug’s previous indications. This label expansion is expected to have ...

$Phathom Pharmaceuticals (PHAT.US)$ FDA Approves VOQUEZNA® for Relief of Heartburn
Associated w/ Non-Erosive GERD in Adults
» now approved for Non-Erosive GERD ✨
» demonstrated rapid heartburn relief in Ph3 trials
» represents the 1st major GERD innovation in 30 years
» the only FDA-approved Tx of its kind available 👏

$Phathom Pharmaceuticals (PHAT.US)$ this is your good chance to ride the bus